Tg Therapeutics (TGTX) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to -$235.8 million.
- Tg Therapeutics' Enterprise Value rose 3085.85% to -$235.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$235.8 million, marking a year-over-year increase of 3085.85%. This contributed to the annual value of -$311.0 million for FY2024, which is 4298.32% down from last year.
- Tg Therapeutics' Enterprise Value amounted to -$235.8 million in Q3 2025, which was up 3085.85% from -$401.6 million recorded in Q2 2025.
- In the past 5 years, Tg Therapeutics' Enterprise Value registered a high of -$139.7 million during Q1 2023, and its lowest value of -$523.8 million during Q1 2021.
- In the last 5 years, Tg Therapeutics' Enterprise Value had a median value of -$233.2 million in 2022 and averaged -$277.6 million.
- As far as peak fluctuations go, Tg Therapeutics' Enterprise Value tumbled by 56872.79% in 2021, and later surged by 5586.76% in 2022.
- Tg Therapeutics' Enterprise Value (Quarter) stood at -$314.8 million in 2021, then surged by 48.64% to -$161.7 million in 2022, then tumbled by 34.53% to -$217.5 million in 2023, then tumbled by 42.98% to -$311.0 million in 2024, then increased by 24.18% to -$235.8 million in 2025.
- Its last three reported values are -$235.8 million in Q3 2025, -$401.6 million for Q2 2025, and -$420.3 million during Q1 2025.